COVID-19 vaccines coding guide
Editor's note: the codes in this article are only active until Nov. 1, 2023. For updated codes, see this post.
The CPT Editorial Panel has approved unique codes for multiple COVID-19 vaccines, as well as administration codes for each dose of those vaccines. This list will be updated as more codes are approved.
| Manufacturer | Vaccine code | Description | Administration codes |
|---|---|---|---|
Pfizer |
91300 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use |
• 0001A (1st dose) • 0002A (2nd dose) • 0003A (3rd dose) • 0004A (booster) |
Moderna |
91301 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use |
• 0011A (1st dose) • 0012A (2nd dose) • 0013A (3rd dose) |
Moderna half-dose booster |
91306 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, for intramuscular use |
• 0064A (booster) |
AstraZeneca/Oxford |
91302 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use |
• 0021A (1st dose) • 0022A (2nd dose) |
| Janssen (Johnson & Johnson) | 91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use | • 0031A (single-dose vaccine) • 0034A (booster) |
| Novavax | 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use | • 0041A (1st dose) • 0042A (2nd dose) |
| Pfizer (tris-sucrose formulation) | 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | • 0051A (first dose) • 0052A (second dose) • 0053A (third dose) |
| Pfizer pediatric (5-11) | 91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use | • 0071A (first dose) • 0072A (second dose) • 0073A (third dose) |
| Pfizer 6 months-5 years | 91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use | • 0081A (first dose) • 0082A (second dose) |
All codes are provisional, pending Emergency Use Authorization or approval by the U.S. Food and Drug Administration. The AMA has published a special edition CPT Assistant guide, which includes an appendix to help identify each vaccine’s product code and administration code.
The AAFP is monitoring every aspect of the COVID-19 vaccine development process, including the Food and Drug Administration's Emergency Use Authorization reviews. Visit aafp.org/covidvaccine for updates to help prepare your practice and patients for the vaccines.
Posted on Jan 06, 2021 by FPM Editors